Industry body Association of Biotechnology Led Enterprises (ABLE) said customs duty of 12.5 per cent, excise/countervailing duty of 16.32 per cent, additional duty on customs of four per cent and two per cent education cess result in 36.74 per cent increase in the price of cancer drugs, leading to cost to the patient going up.
Vijay Chandru, the President of ABLE, said that to provide a fillip to the services sector, ABLE would like to see extension of service tax exemption to pre-clinical studies in the coming Union budget"Currently, only clinical trials are exempt from service tax and there is no rationale to exclude pre-clinical studies from this exemption," Chandru, also the Chairman and CEO of Strand Life Sciences, said.
To accelerate the growth of the Indian biotech sector and make it a globally-strong industry, the government needs to ensure a robust, unambiguous, time-bound and transparent regulatory.
Chandru also said, "the government should set up a world-class, internationally recognised, accreditation agency which can set standards and protocols that are in harmony with global regulations and standards."
The biotech industry has also sought tax concessions, such as, weighted average tax deduction of 150 per cent on all market development expenditure pertaining to innovator products, 10-year excise duty exemption on all innovator products manufactured in the country and customs duty exemption for all innovator products produced in Special Economic Zones (SEZ) in India for a 10-year period from the date of marketing approval"The industry needs weighted average tax deduction on R&D expenditure and inclusion of international patent filing costs and market development costs u/s 35 (2AB)," he further added.
To spur manufacturing, ABLE has sought the removal of customs and excise duty on raw materials and components used by domestic manufacturers for production of life-saving drugs and diagnostics as the finished products are allowed to be imported duty-free.
Kiran Mazumdar-Shaw, head of Biocon Ltd, said a 10-year tax holiday is needed on all indigenously developed biotech drugs and products to act as an investment incentive for R&D.. "Five years is simply not enough to compete with MNCs who enjoy much higher drugs prices, thanks to a skewed way of deriving price levels which is based on unverified transfer pricing in the case of MNCs and audited cost prices for Indian companies," she said.
The industry has also sought SEZ-like incentives for biotech export oriented units
Monday, February 22, 2010
Biotech cos for tax exemption for cancer drug R&D
Industry Research Reports
LIC Term Insurance or Pvt Life Insurance Term Plan ? Which is the best term insurance in India ? Which Insurance company has the best cla...
આજકાલ કોઈપણ સમસ્યા હોય લોકો એન્ટિબાયોટિક્સ અંગ્રેજી દવાઓ લેવાનું વધુ પસંદ કરતાં હોય છે કારણ કે આજની પેઢીને આપણા જુનવાણી નુસખા વિશે જાણ હોત...
http://www.livemint.com/2007/12/13162756/SBI-UTI-MFs-to-manage-post-of.html New Delhi: Government has appointed PSU mutual funds UTI MF a...
સુરતી લોચો બનાવવાની રીત Surati Locho - સુરતી લોચો લોચો એ ગુજરાતની સૌથી સ્વાદિષ્ટ ચટપટી ખાવાની ચીજો પૈકીની એક ચીજ છે. લોચો બનાવવાની ...
i-Develop Multibagger Stock Performance last year Enter Date Exit Date Bse Code Scri...
NTPC and RIL are fighting a case in the Bombay High Court over gas pricing for the former's Kawas and Gandar power plants....
Global private equity giant The Blackstone Group has announced that it has bought a majority stake in CMS Computers Ltd. Black...
નવાઝ શરીફ સાથે મુલાકાત બપોરે પાકિસ્તાનના વડાપ્રધાન નવાઝ શરીફ અને નરેન્દ્ર મોદી વચ્ચે વાતચીત થઈ ગઈ હતી. બંને નેતાએ લગભગ 26 સેકન્ડ સુધી ...